Q1 EPS Estimates for Journey Medical Reduced by Roth Capital

Journey Medical Co. (NASDAQ:DERM) – Research analysts at Roth Capital reduced their Q1 2025 EPS estimates for Journey Medical in a research note issued to investors on Thursday, March 27th. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0.19) per share for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical’s Q2 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.05 EPS, FY2026 earnings at $2.18 EPS, FY2027 earnings at $3.32 EPS and FY2028 earnings at $5.18 EPS.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings results on Wednesday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.30. The company had revenue of $14.30 million during the quarter, compared to analysts’ expectations of $14.21 million. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%.

Separately, Alliance Global Partners reissued a “buy” rating on shares of Journey Medical in a research report on Thursday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $9.67.

Journey Medical Price Performance

Shares of NASDAQ:DERM opened at $6.11 on Monday. The company has a market cap of $127.64 million, a price-to-earnings ratio of -6.50 and a beta of 0.97. The business has a 50 day moving average price of $5.09 and a 200 day moving average price of $5.17. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. Journey Medical has a twelve month low of $3.20 and a twelve month high of $6.89.

Hedge Funds Weigh In On Journey Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tang Capital Management LLC acquired a new position in Journey Medical in the fourth quarter worth about $6,747,000. Cetera Investment Advisers grew its stake in shares of Journey Medical by 21.8% in the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock valued at $54,000 after purchasing an additional 2,478 shares during the period. Citadel Advisors LLC acquired a new position in shares of Journey Medical in the 4th quarter worth approximately $174,000. Kovitz Investment Group Partners LLC lifted its position in shares of Journey Medical by 112.9% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock worth $97,000 after buying an additional 13,105 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in Journey Medical in the 4th quarter valued at $80,000. 7.25% of the stock is owned by institutional investors.

Insider Activity at Journey Medical

In other Journey Medical news, CEO Claude Maraoui sold 23,508 shares of Journey Medical stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $5.19, for a total transaction of $122,006.52. Following the sale, the chief executive officer now owns 2,139,922 shares in the company, valued at $11,106,195.18. The trade was a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 105,831 shares of company stock worth $536,622 over the last three months. Company insiders own 13.16% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.